GeneReviews - Pompe disease (targeted treatment)
GeneReviews, University of Washington
GeneReviews chapter on Pompe disease, covering CRIM status, immune tolerance induction and the targeted treatment of infantile-onset disease.
Open sourceCheck bedside glucose immediately in any acutely unwell child. Encephalopathy, rising ammonia, severe acidosis or refractory hypoglycaemia: call metabolic genetics and PICU early. Treat shock, seizures and possible sepsis in parallel - in a sick child, treatment takes priority over the critical sample.
GeneReviews, University of Washington
GeneReviews chapter on Pompe disease, covering CRIM status, immune tolerance induction and the targeted treatment of infantile-onset disease.
Open sourceAmerican College of Medical Genetics and Genomics · 2025
Evidence-based recommendations for phenylalanine hydroxylase deficiency, including lifelong treatment when untreated phenylalanine exceeds 360 micromol/L and a treatment target of 360 micromol/L or less.
Open sourceGeneReviews, University of Washington · 2024
Diagnosis and treatment of biotinidase deficiency, including free biotin dosing for profound and partial deficiency and the need for hearing and vision assessment.
Open sourceGeneReviews, University of Washington · 2024
Management of MCAD deficiency, including the acute illness glucose infusion of 1.5 times maintenance or a GIR of 10-12 mg/kg/min and fasting prevention.
Open sourceGeneReviews, University of Washington · 2024
Clinical description, diagnosis and management of MSUD, including the inpatient branched-chain amino acid and BCAA-free formula regimen.
Open sourceRoyal Children's Hospital Melbourne · 2024
Assessment and management of hypoglycaemia in children, including the critical sample during hypoglycaemia and initial dextrose therapy.
Open sourceRoyal Children's Hospital Melbourne · 2024
Emergency and ward approach to suspected inborn errors of metabolism, including initial assessment, critical samples and the first pattern-based differential.
Open sourceGeneReviews, University of Washington · 2024
Diagnosis and management of tyrosinemia type I, including nitisinone dosing, dietary restriction and the monitoring schedule.
Open sourceNationwide Children's Hospital · 2024
A neonatal pathway for hyperammonaemia giving example levocarnitine and hydroxocobalamin regimens used in suspected organic acidaemia.
Open sourceEuropean Medicines Agency · 2023
Label dosing for carglumic acid in acute hyperammonaemia due to NAGS deficiency and in organic acidaemias, with renal adjustment guidance.
Open sourceJournal of Inherited Metabolic Disease · 2021
Consensus management guidelines for methylmalonic and propionic acidaemia, covering acute decompensation, carnitine and cobalamin therapy and long-term diet.
Open sourceU.S. Food and Drug Administration · 2020
U.S. label starting doses of sapropterin by age and the 5-20 mg/kg/day titration range for BH4-responsive PAH deficiency.
Open sourceNo sources are linked to this topic yet. Browse the full guidelines and literature list.
20 mg/kg IV every 2 weeks.
Monitor: Respiratory and motor function, infusion-associated reactions and anti-drug antibodies per the centre protocol.
Confirmed urea-cycle disorder: the cited label table lists 200 mg/kg for OTC/CPS1 and 600 mg/kg for ASS1/ASL, over 90-120 min, then the same dose over 24 hr.
Monitor: Plasma ammonia, amino acids and electrolytes; follow with the specialist metabolic centre.
2-3.5 g/kg/day total protein equivalents in the cited inpatient regimen. Select the product, route and energy prescription with the metabolic dietitian.
Monitor: Plasma branched-chain amino acids, glucose, sodium, osmolality and phosphorus.
Profound biotinidase deficiency: 5-10 mg PO daily as a fixed daily dose. Partial deficiency: GeneReviews lists 2.5-10 mg PO daily, with practice variation.
Monitor: Serum biotinidase activity, with hearing and vision assessment.
Acute NAGS deficiency: 100-250 mg/kg/day divided in 2-4 doses. Acute PA/MMA hyperammonaemia: 150 mg/kg/day if 15 kg or less; 3.3 g/m2/day if over 15 kg, given PO or enteral tube in 2 divided doses, continuing until ammonia is below 50 micromol/L for up to 7 days per label.
Monitor: Plasma ammonia and clinical status.
Intraventricular every 2 weeks via a surgically implanted reservoir, followed by the labelled intraventricular electrolyte solution: birth to under 6 months 100 mg; 6 months to under 1 year 150 mg; 1 year to under 2 years 200 mg for the first 4 doses then 300 mg; 2 years and older 300 mg.
Monitor: CSF surveillance, device checks, seizure frequency and motor-language scores.
10% dextrose 2 mL/kg IV for severe hypoglycaemia under the pediatric emergency protocol, followed by a glucose infusion or appropriate feeds. D10 at 4.8 mL/kg/hr delivers 8 mg/kg/min. Calculate the actual GIR and adjust electrolytes and fluid volume for age, cardiac function and neurologic status.
Monitor: Bedside glucose, GIR, electrolytes, osmolality and fluid balance.
2 mg/kg IV once weekly.
Monitor: Urinary keratan sulfate, six-minute walk test and respiratory function.
1 mg/kg IV once weekly.
Monitor: Urinary glycosaminoglycans, endurance and joint mobility.
Suspected responsive methylmalonic acidaemia: 1 mg IM is a neonatal pathway initial dose. The stable-state responsiveness protocol uses 1 mg IM daily on 3 consecutive days with serial methylmalonate under metabolic supervision.
Monitor: Serial methylmalonate, plasma amino acids and total homocysteine.
0.5 mg/kg IV once weekly.
Monitor: Urinary glycosaminoglycans, six-minute walk test, respiratory and cardiac function.
2.5 units/kg IV three times weekly up to 60 units/kg IV every 2 weeks. Individualize by disease severity and treatment goals.
Monitor: Haemoglobin, platelet count, spleen and liver volume, bone disease and biomarker response.
20-120 mg/kg/day each, enteral and/or parenteral under metabolic supervision, adjusted to measured amino acids and clinical response.
Monitor: Serial plasma branched-chain amino acids (leucine, isoleucine and valine) and clinical response.
0.58 mg/kg IV once weekly.
Monitor: Urinary glycosaminoglycans, liver and spleen volume, respiratory function and joint mobility.
Example neonatal emergency pathway: 50 mg/kg IV or enteral loading, then 100 mg/kg/day IV or enteral, continuous or divided every 6-8 hr. Confirm with the metabolic team.
Monitor: Plasma carnitine, ammonia, blood gas, electrolytes, glucose and urine output.
Chronic targeted treatment: 100-200 mg/kg/day PO in 3 doses, titrated to plasma carnitine.
Monitor: Plasma free and total carnitine; cardiac function where cardiomyopathy is suspected.
Starting dose 0.5 mg/kg/dose PO twice daily. Titrate with the specialist per label, up to 2 mg/kg/day.
Monitor: Succinylacetone, amino acids, AFP, liver imaging and drug levels according to the centre protocol.
For non-CNS manifestations, IV every 2 weeks with stepwise escalation in mg/kg: week 0 0.03, week 2 0.1, weeks 4 and 6 0.3, weeks 8 and 10 0.6, week 12 1, week 14 2, week 16 3. Continue 3 mg/kg IV every 2 weeks after the first 3 mg/kg dose.
Monitor: ALT, AST, spleen and liver volume, lung function and infusion-associated reactions.
Subcutaneous. Induction: 2.5 mg once weekly for 4 weeks. Titration: if tolerated, at least 1 week per step - 2.5 mg twice weekly, 10 mg once weekly, 10 mg twice weekly, 10 mg four times weekly, then 10 mg daily. Maintenance: start 20 mg daily; if control is inadequate after at least 24 continuous weeks consider 40 mg daily; if still inadequate after at least 16 continuous weeks at 40 mg consider 60 mg daily (maximum). Discontinue if the response remains inadequate after 16 continuous weeks at 60 mg daily.
Monitor: Blood phenylalanine at baseline and during treatment; hypersensitivity and anaphylaxis.
Rapidly progressive disease presenting in the first 6 months of life: 1 mg/kg IV once weekly, increasing to 3 mg/kg weekly and then 5 mg/kg weekly if the response is suboptimal. Other pediatric patients: 1 mg/kg IV every 2 weeks, increasing to 3 mg/kg every 2 weeks if the response is suboptimal.
Monitor: ALT, AST, lipid profile, liver volume and growth.
Each component: 250 mg/kg if 20 kg or less; 5.5 g/m2 if over 20 kg. Give the loading dose over 90-120 min, then the same amount of each over 24 hr. Dilute in D10 and use central access per label.
Monitor: Ammonia every 1-2 hours early in a severe crisis, mental status, glucose, sodium, potassium and acid-base status.
No medication doses are linked to this topic yet. See the full dose reference.